Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

CYP3A5{*}3 and CYP2C8{*}3 variants influence exposure and clinical outcomes of tacrolimus-based therapy

Texto completo
Autor(es):
Mostrar menos -
Genvigir, Fabiana Dalla Vecchia [1] ; Brayan Campos-Salazar, Antony [1, 2] ; Felipe, Claudia Rosso [3] ; Tedesco-Silva Jr, Helio ; Medina-Pestana, Jose Osmar [4] ; Doi, Sonia de Quateli [5] ; Cerda, Alvaro [6] ; Hirata, Mario Hiroyuki [1] ; Herrero, Maria Jose [7, 8] ; Alino, Salvador Francisco [7, 8] ; Crespo Hirata, Rosario Dominguez [1]
Número total de Autores: 11
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo - Brazil
[2] Univ Nacl Mayor San Marcos, Sch Pharm & Biochem, Bioinformat & Pharmacogenet Lab, METOSMOD Res Grp, Lima - Peru
[3] Univ Fed Sao Paulo, Hosp Rim, Nephrol Div, Sao Paulo - Brazil
[4] Tedesco-Silva Jr, Jr., Helio, Univ Fed Sao Paulo, Hosp Rim, Nephrol Div, Sao Paulo - Brazil
[5] Uniformed Serv Univ Hlth Sci, Sch Med, Nephrol Res Lab, Bethesda, MD - USA
[6] Univ La Frontera, Ctr Excellence Translat Med, Dept Basic Sci, BIOREN, Temuco - Chile
[7] Univ Valencia Pharmacogenet, Inst Invest Sanitaria, Dept Pharmacol, Valencia - Spain
[8] Hosp La Fe, Valencia - Spain
Número total de Afiliações: 8
Tipo de documento: Artigo Científico
Fonte: PHARMACOGENOMICS; v. 21, n. 1, p. 7-21, JAN 2020.
Citações Web of Science: 0
Resumo

Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients \& methods: Brazilian kidney recipients were treated with TAC combined with everolimus (n = 178) or mycophenolate sodium (n = 97). The variants in CYP2C8, CYP2J2, CYP3A4, CYP3A5, POR, ABCB1, ABCC2, ABCG2, SLCO1B1 and SLCO2B1 were analyzed. Main results:CYP3A5{*}3/{*}3 genotype influenced increase in TAC concentration from week 1 to month 6 post-transplantation (p < 0.05). The living donor and CYP2C8{*}3 variant were associated with reduced risk for delayed graft function (OR = 0.07; 95% CI = 0.03-0.18 and OR = 0.45; 95% CI = 0.20-0.99, respectively, p < 0.05). Conclusion: The CYP3A5{*}3 variant is associated with increased early exposure to TAC. Living donor and CYP2C8{*}3 variant seem to be protective factors for delayed graft function in kidney recipients. (AU)

Processo FAPESP: 16/13118-8 - Fatores farmacogenômicos e epigenômicos relacionados com a resposta a imunossupressores em receptores de transplante renal
Beneficiário:Rosario Dominguez Crespo Hirata
Linha de fomento: Auxílio à Pesquisa - Regular